Trial Profile
A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase III Clinical Study Evaluating the Efficacy and Safety of Favipiravir in the Treatment of Patients With COVID-19-Moderate Type
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 10 Apr 2022
Price :
$35
*
At a glance
- Drugs Favipiravir (Primary)
- Indications COVID 2019 infections
- Focus Therapeutic Use
- 08 Apr 2020 New trial record